{"id":"NCT01264939","sponsor":"Genentech, Inc.","briefTitle":"A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists","officialTitle":"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2010-12-22","resultsPosted":"2013-11-26","lastUpdate":"2013-11-26"},"enrollment":336,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Idiopathic Urticaria"],"interventions":[{"type":"DRUG","name":"Omalizumab","otherNames":["Xolair"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist","otherNames":[]},{"type":"DRUG","name":"Diphenhydramine","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Omalizumab 300 mg","type":"EXPERIMENTAL"}],"summary":"The study is a global Phase III, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate the safety and efficacy of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and adult patients aged 12-75 who have been diagnosed with chronic idiopathic urticaria (CIU) who remain symptomatic despite standard-dosed H1 antihistamine treatment (including doses up to 4 times above the approved dose level), H2 blockers, and/or leukotriene receptor antagonists (LTRA).","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events","timeFrame":"Baseline to the end of study (up to 40 weeks)","effectByArm":[{"arm":"Placebo","deltaMin":78.3,"sd":null},{"arm":"Omalizumab 300 mg","deltaMin":83.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":14},"locations":{"siteCount":73,"countries":["United States","Australia","Germany","New Zealand","Poland","Singapore","Switzerland","United Kingdom"]},"refs":{"pmids":["29655772","28390587","27939380","27540466","27424128","26054553"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":83},"commonTop":["Idiopathic urticaria","Sinusitis","Nasopharyngitis","Upper respiratory tract infection","Headache"]}}